Back

Latest Forum Topics / UGHealthcare    Last:0.084    -0.002

Post Reply

Hyphen Pharma Post Reply Rate topic
Success3288 Member	24-Jan-2021 09:59        Success3288 About Contact  Quote this Post!
x 0   x 0  Alert Admin	UG result out 4 Feb 21 0.8 coming soon.  Huat!
Useful To Me  Not Useful To Me
lsyiat Veteran	23-Jan-2021 19:30        lsyiat About Contact  Quote this Post!
x 0   x 0  Alert Admin	Hospitals seeing shortages of gloves https://www.wbrc.com/2021/01/22/hospitals-seeing-shortages-gloves/
Useful To Me  Not Useful To Me
FreedomAngelz Veteran	23-Jan-2021 18:42        FreedomAngelz About Contact  Quote this Post!
x 0   x 0  Alert Admin	9 trading day away from result release....9 day away for shortist to cover......9 day away from more huat.
Useful To Me  Not Useful To Me
Shifu8888 Supreme	23-Jan-2021 16:46        Shifu8888 About Contact  Quote this Post!
x 0   x 0  Alert Admin	My word will be used again and again: Wild geese chase Vaccine against Variant Singapore succeeds and rest of world dies. So what next? look@bright      ( Date: 23-Jan-2021 16:22) Posted: MATT Hancock has warned Covid vaccines may be 50% less effective against the new mutant South African strain - putting us " back to square one" . https://www.thesun.co.uk/news/13823271/matt-hancock-south-african-strain-covid-jabs/
Useful To Me  Not Useful To Me
look@bright Elite	23-Jan-2021 16:22        look@bright About Contact  Quote this Post!
x 0   x 0  Alert Admin	MATT Hancock has warned Covid vaccines may be 50% less effective against the new mutant South African strain - putting us " back to square one" . https://www.thesun.co.uk/news/13823271/matt-hancock-south-african-strain-covid-jabs/
Useful To Me  Not Useful To Me
look@bright Elite	23-Jan-2021 15:47        look@bright About Contact  Quote this Post!
x 0   x 0  Alert Admin	Fauci says lack of candor from Trump administration ' very likely' cost lives
Useful To Me  Not Useful To Me
Shifu8888 Supreme	23-Jan-2021 12:32        Shifu8888 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Let me repeat vaccine is not going to help. Unlike Spanish flu era, people are super mobile now, carrying the virus everywhere. The speed of vaccination needs to catch up with the speed of: 1. Spreading 2. Mutation of new variants No chance. This world is doomed. Gg for humanity. look@bright      ( Date: 23-Jan-2021 12:15) Posted: after 2 years maybe another virus will start another pandemic? stanip      ( Date: 23-Jan-2021 12:13) Posted: For those who are interested in estimating when the vaccine line will cross the covid infection line (i.e. Herb immunity equilibrium point), this is an intersting article I came across.  Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination - The Lancet https://www.thelancet.com/article/S0140-6736(20)32318-7/fulltext#sec1   The mathematical model seems to be pointing to 2 years after start of vaccination.  Other interpretation or observations?  " Calculations of the proportion of the population that will need to be immunised year by year with a COVID-19 vaccine of defined properties can be derived from transmission models of SARS-CoV-2 (appendix). The simple equation for coverage pcbecomes a more complicated expression that involves the rate at which people are immunised, & epsilon , the magnitude of R0, and the average duration of protection provided by the vaccine (figure). The surface plotted in the figure shows the percentage of the population in year 1 that must be vaccinated and a similar plot of the percentage that must be vaccinated once the system equilibrates after a few years. A rough idea of this time is given by numerical evaluations of the model and gives  equilibration by the end of year 2  (appendix). The percentage of the population that must be vaccinated in year 1 is much larger than the percentage that must be vaccinated once the system has stabilised after a few years, since most of the population will be susceptible as mass immunisation starts, but after a few years, hopefully, a high proportion will be immunised such that effective herd immunity is created. What is clear from our estimates based on the assumptions that efficacy is satisfactory (> 80%) but duration of protection is short (1& ndash 2 years), is that a large proportion of the total population would need to be vaccinated if there is to be any chance of getting herd immunity to block the continued transmission of SARS-CoV-2."
Useful To Me  Not Useful To Me
look@bright Elite	23-Jan-2021 12:15        look@bright About Contact  Quote this Post!
x 0   x 0  Alert Admin	after 2 years maybe another virus will start another pandemic? stanip      ( Date: 23-Jan-2021 12:13) Posted: For those who are interested in estimating when the vaccine line will cross the covid infection line (i.e. Herb immunity equilibrium point), this is an intersting article I came across.  Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination - The Lancet https://www.thelancet.com/article/S0140-6736(20)32318-7/fulltext#sec1   The mathematical model seems to be pointing to 2 years after start of vaccination.  Other interpretation or observations?  " Calculations of the proportion of the population that will need to be immunised year by year with a COVID-19 vaccine of defined properties can be derived from transmission models of SARS-CoV-2 (appendix). The simple equation for coverage pcbecomes a more complicated expression that involves the rate at which people are immunised, & epsilon , the magnitude of R0, and the average duration of protection provided by the vaccine (figure). The surface plotted in the figure shows the percentage of the population in year 1 that must be vaccinated and a similar plot of the percentage that must be vaccinated once the system equilibrates after a few years. A rough idea of this time is given by numerical evaluations of the model and gives  equilibration by the end of year 2  (appendix). The percentage of the population that must be vaccinated in year 1 is much larger than the percentage that must be vaccinated once the system has stabilised after a few years, since most of the population will be susceptible as mass immunisation starts, but after a few years, hopefully, a high proportion will be immunised such that effective herd immunity is created. What is clear from our estimates based on the assumptions that efficacy is satisfactory (> 80%) but duration of protection is short (1& ndash 2 years), is that a large proportion of the total population would need to be vaccinated if there is to be any chance of getting herd immunity to block the continued transmission of SARS-CoV-2."
Useful To Me  Not Useful To Me
stanip Veteran	23-Jan-2021 12:13        stanip About Contact  Quote this Post!
x 0   x 0  Alert Admin	For those who are interested in estimating when the vaccine line will cross the covid infection line (i.e. Herb immunity equilibrium point), this is an intersting article I came across.  Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination - The Lancet https://www.thelancet.com/article/S0140-6736(20)32318-7/fulltext#sec1   The mathematical model seems to be pointing to 2 years after start of vaccination.  Other interpretation or observations?  " Calculations of the proportion of the population that will need to be immunised year by year with a COVID-19 vaccine of defined properties can be derived from transmission models of SARS-CoV-2 (appendix). The simple equation for coverage pcbecomes a more complicated expression that involves the rate at which people are immunised, & epsilon , the magnitude of R0, and the average duration of protection provided by the vaccine (figure). The surface plotted in the figure shows the percentage of the population in year 1 that must be vaccinated and a similar plot of the percentage that must be vaccinated once the system equilibrates after a few years. A rough idea of this time is given by numerical evaluations of the model and gives  equilibration by the end of year 2  (appendix). The percentage of the population that must be vaccinated in year 1 is much larger than the percentage that must be vaccinated once the system has stabilised after a few years, since most of the population will be susceptible as mass immunisation starts, but after a few years, hopefully, a high proportion will be immunised such that effective herd immunity is created. What is clear from our estimates based on the assumptions that efficacy is satisfactory (> 80%) but duration of protection is short (1& ndash 2 years), is that a large proportion of the total population would need to be vaccinated if there is to be any chance of getting herd immunity to block the continued transmission of SARS-CoV-2."
Useful To Me  Not Useful To Me
grateful Senior	22-Jan-2021 17:02        grateful About Contact  Quote this Post!
x 0   x 0  Alert Admin	Give CNY angbao earlier, then we can go shopping and enjoy the joyous occasion.  Huat ah! Longtermer      ( Date: 22-Jan-2021 15:04) Posted: Mgtm advances results announcement by 1 week.. Why kang chiong to announce? Must be v v good i think.. huat Success3288      ( Date: 22-Jan-2021 14:40) Posted: 4 FEB 21  UG Release Results  HUAT! Soon can see 0.80
Useful To Me  Not Useful To Me
Longtermer Elite	22-Jan-2021 15:04        Longtermer About Contact  Quote this Post! Style: Flexible   Yells: "A disciplined investor is a wealthy investor"
x 0   x 0  Alert Admin	Mgtm advances results announcement by 1 week.. Why kang chiong to announce? Must be v v good i think.. huat Success3288      ( Date: 22-Jan-2021 14:40) Posted: 4 FEB 21  UG Release Results  HUAT! Soon can see 0.80
Useful To Me  Not Useful To Me
Success3288 Member	22-Jan-2021 14:40        Success3288 About Contact  Quote this Post!
x 0   x 0  Alert Admin	4 FEB 21  UG Release Results  HUAT! Soon can see 0.80
Useful To Me  Not Useful To Me
Shifu8888 Supreme	22-Jan-2021 13:58        Shifu8888 About Contact  Quote this Post!
x 0   x 0  Alert Admin	I will give it a steroid shot Soon Watch it.... run 🐎 🐎 🐎 🐎
Useful To Me  Not Useful To Me
FreedomAngelz Veteran	21-Jan-2021 17:37        FreedomAngelz About Contact  Quote this Post!
x 1   x 0  Alert Admin	UG posting result end of 4th Feb...exactly 10 trading days. Huaaat ah
Useful To Me  Not Useful To Me
ss2017. Supreme	21-Jan-2021 16:36        ss2017. About Contact  Quote this Post!
x 1   x 0  Alert Admin	It seems people are collecting systematically, I think 85 is coming faster than expected. Just wait ss2017.      ( Date: 21-Jan-2021 09:24) Posted: Today low volume, collection time next surge would be 80 then 85
Useful To Me  Not Useful To Me
Shifu8888 Supreme	21-Jan-2021 15:57        Shifu8888 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Relax
Useful To Me  Not Useful To Me
ss2017. Supreme	21-Jan-2021 15:56        ss2017. About Contact  Quote this Post!
x 0   x 0  Alert Admin	Intraday correction from 76.5 to 72.5 and current  price 74.5 correction is done. Waiting for page 8 Longtermer      ( Date: 21-Jan-2021 15:28) Posted: A recollection of UG earnings given in Nov 2020 below. Note that UG was trading at 98c when Q3 was announced last Nov.. we are now looking fwd to UG Half Year results around 2nd week Feb just bf CNY. What will be the coming Full Year earnings be like? Going to be More or Less ? What will be the UG price then? Is current price 74.5c justified? DYODD and position to huat.. ------------------------ UG Healthcare posts 74-fold increase in Q1 net profit to S$22.7m Thu, Nov 05, 2020 Uma Devi GLOVE manufacturer UG Healthcare Corporation on Thursday reported net profit of S$22.7 million for the first fiscal quarter ended September, a 74-fold increase from net profit of S$305,000 in the corresponding quarter last year. The group' s latest quarterly profit had also exceeded its FY2020 net profit of S$13.4 million, said the group in a bourse filing. UG Healthcare' s revenue for the quarter rose 170.6 per cent to S$71.2 million from S$26.3 million in the year-ago period, due to a higher volume of gloves sold as well as higher average selling prices on the back of stronger demand for disposable gloves and supply constraints. The group' s revenue contributions from Europe, South America, Africa and Asia each more than doubled in the period under review, while the North America and others regions booked increases of 28.3 per cent and 41.3 per cent respectively. Segmentally, UG Healthcare said its downstream distribution business has continued to see growing demand in all key markets for both developed and developing countries. The upstream manufacturing business is also operating at its " optimum efficiency" of 2.9 billion pieces of gloves per annum, producing both nitrile and natural latex examination gloves. Some 85 per cent of these gloves are sold in UG Healthcare' s own brand, Unigloves, through its downstream distribution companies, the company added. On the back of improved margins for both its upstream and downstream business segments, UG Healthcare' s gross margin for the quarter came in at 60.6 per cent, up by 41.7 percentage points year-on-year. The company said that operating expenses for the quarter were " relatively stable" , and its finance costs had been reduced due to lower borrowings. Short-term borrowings were also reduced significantly on the back of stronger operating cash flow, and the company remains in a net cash position as at end-September. UG Healthcare said it is on track to achieve its production capacity expansion plans to cope with the higher demand for gloves that was brought about by the Covid-19 pandemic. On Sept 8, the company said it has commenced work on a new manufacturing facility in Malaysia that will boost its production capacity by 1.2 billion pieces of gloves per annum. The company is also looking to expand its production lines to produce an additional 500 million pieces of gloves per annum, which would bring its total production capacity to 3.4 billion pieces of gloves by end-March 2021. UG Healthcare executive director and finance director Lee Jun Yih said: " We believe that our group' s strategy will drive production volume in our upstream manufacturing, and enhance flexibility and sustainability in our business operations." He added that the company is also expecting to benefit from further economies of scale beyond FY2021 with the additional capacity. UG Healthcare said it has used some S$4.6 million out of the S$18.4 million in net proceeds that it had raised from the placement of 7.5 million new shares that was completed on Aug 21. The group has utilised S$3.7 million of this amount for capital expenditure for production capacity expansion plans, while the remaining S$0.9 million was used for general working capital purposes. UG Healthcare shares closed at S$0.98 on Thursday prior to the results announcement, up 2.6 per cent or 2.5 Singapore cents. Ichimoku      ( Date: 20-Jan-2021 09:23) Posted: --- Post Removed by User ---
Useful To Me  Not Useful To Me
Longtermer Elite	21-Jan-2021 15:28        Longtermer About Contact  Quote this Post! Style: Flexible   Yells: "A disciplined investor is a wealthy investor"
x 0   x 0  Alert Admin	A recollection of UG earnings given in Nov 2020 below. Note that UG was trading at 98c when Q3 was announced last Nov.. we are now looking fwd to UG Half Year results around 2nd week Feb just bf CNY. What will be the coming Full Year earnings be like? Going to be More or Less ? What will be the UG price then? Is current price 74.5c justified? DYODD and position to huat.. ------------------------ UG Healthcare posts 74-fold increase in Q1 net profit to S$22.7m Thu, Nov 05, 2020 Uma Devi GLOVE manufacturer UG Healthcare Corporation on Thursday reported net profit of S$22.7 million for the first fiscal quarter ended September, a 74-fold increase from net profit of S$305,000 in the corresponding quarter last year. The group' s latest quarterly profit had also exceeded its FY2020 net profit of S$13.4 million, said the group in a bourse filing. UG Healthcare' s revenue for the quarter rose 170.6 per cent to S$71.2 million from S$26.3 million in the year-ago period, due to a higher volume of gloves sold as well as higher average selling prices on the back of stronger demand for disposable gloves and supply constraints. The group' s revenue contributions from Europe, South America, Africa and Asia each more than doubled in the period under review, while the North America and others regions booked increases of 28.3 per cent and 41.3 per cent respectively. Segmentally, UG Healthcare said its downstream distribution business has continued to see growing demand in all key markets for both developed and developing countries. The upstream manufacturing business is also operating at its " optimum efficiency" of 2.9 billion pieces of gloves per annum, producing both nitrile and natural latex examination gloves. Some 85 per cent of these gloves are sold in UG Healthcare' s own brand, Unigloves, through its downstream distribution companies, the company added. On the back of improved margins for both its upstream and downstream business segments, UG Healthcare' s gross margin for the quarter came in at 60.6 per cent, up by 41.7 percentage points year-on-year. The company said that operating expenses for the quarter were " relatively stable" , and its finance costs had been reduced due to lower borrowings. Short-term borrowings were also reduced significantly on the back of stronger operating cash flow, and the company remains in a net cash position as at end-September. UG Healthcare said it is on track to achieve its production capacity expansion plans to cope with the higher demand for gloves that was brought about by the Covid-19 pandemic. On Sept 8, the company said it has commenced work on a new manufacturing facility in Malaysia that will boost its production capacity by 1.2 billion pieces of gloves per annum. The company is also looking to expand its production lines to produce an additional 500 million pieces of gloves per annum, which would bring its total production capacity to 3.4 billion pieces of gloves by end-March 2021. UG Healthcare executive director and finance director Lee Jun Yih said: " We believe that our group' s strategy will drive production volume in our upstream manufacturing, and enhance flexibility and sustainability in our business operations." He added that the company is also expecting to benefit from further economies of scale beyond FY2021 with the additional capacity. UG Healthcare said it has used some S$4.6 million out of the S$18.4 million in net proceeds that it had raised from the placement of 7.5 million new shares that was completed on Aug 21. The group has utilised S$3.7 million of this amount for capital expenditure for production capacity expansion plans, while the remaining S$0.9 million was used for general working capital purposes. UG Healthcare shares closed at S$0.98 on Thursday prior to the results announcement, up 2.6 per cent or 2.5 Singapore cents. Ichimoku      ( Date: 20-Jan-2021 09:23) Posted: --- Post Removed by User ---
Useful To Me  Not Useful To Me
ss2017. Supreme	21-Jan-2021 09:24        ss2017. About Contact  Quote this Post!
x 0   x 0  Alert Admin	Today low volume, collection time next surge would be 80 then 85
Useful To Me  Not Useful To Me
uncle2020 Senior	21-Jan-2021 08:46        uncle2020 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Biden now in charge, brings cheer to UG ? today up up...break 77 ? possible ?
Useful To Me  Not Useful To Me

                                                         First   < Newer   1081-1100 of 1294   Older>   Last